Sponsor Check › Person
Related person on Form D filings · address states/countries as listed: CA, TX, NC, NY, MA, United Kingdom (as filed: X0), FL · listed Aug 13, 2009 → Nov 7, 2023
Data last updated: Oct 23, 2026, 5:45 PM ET · Courts (RECAP) last checked: Oct 23, 2026, 11:57 PM ET · SEC enforcement last checked: not yet
Privacy: business-related public information only. Residential addresses are never shown; only the state from the filing.
The five facts investors ask about first. Each section states what was searched and when. Items still in human review are not shown.
None found in sources searched.
Sources searched: CourtListener bulk data (RECAP dockets as of 2026-09-30) — federal district + bankruptcy courts; live RECAP re-check pending. State courts: not yet searched. PACER: not searched. · Last checked Oct 23, 2026, 11:57 PM ET.
State courts: not yet searched. No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.
SEC enforcement searched: SEC litigation releases and administrative proceedings — respondent names in the sec.gov index titles (30,205 releases, 1995-09-19 to 2026-10-23); release text is read only to confirm a candidate. Names that appear only in the body of a release are not found. — not yet searched; State securities regulators searched: AZ (Corporation Commission Securities Division), CA (DFPI — 16 of 12,159 DFPI respondent pages read so far; sponsor-name matches are read first), DE (DOJ Investor Protection Unit), TX (State Securities Board), WA (DFI) — last crawled Oct 23, 2026, 9:57 PM ET. Other states: not yet searched.
Not yet searched.
No SEC search has run yet for this person.
None found in sources searched.
Sources searched: Federal bankruptcy courts via CourtListener / RECAP archive (federal district courts, federal bankruptcy courts). State courts: not yet searched. PACER: not searched (RECAP only). · Last checked Oct 23, 2026, 11:57 PM ET.
State courts: not yet searched. No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.
Comparisons are made for sponsors and sponsor groups, not individual people.
2 of 37 offerings report sales commissions totalling $1,281,837; 1 reports finder's fees totalling $11,737; 5 report proceeds to related persons totalling $98,391,539. (includes amounts the issuer reported as estimates)
| Source | Offering (latest filing) | Sales commissions | Finder's fees | To insiders | Paid to sell it |
|---|---|---|---|---|---|
| EDGAR ↗ | Jun 24, 2026 D File 021-588459 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Mar 7, 2025 D/A File 021-507625 | $0 | $0 | $0 | Mt. Vernon Capital, LLC BrokerCheck CRD 36402 ↗ via Britehorn Securities |
| EDGAR ↗ | Nov 21, 2024 D File 021-530130 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Nov 7, 2023 D File 021-496597 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Mar 1, 2023 D File 021-474622 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jun 14, 2021 D File 021-402804 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jul 16, 2019 D File 021-344358 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jul 15, 2019 D File 021-344332 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | May 29, 2019 D File 021-340600 | $0 | $0 | $190,520 Paying CEO. | None listed on this filing |
| EDGAR ↗ | Apr 22, 2019 D File 021-337783 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jun 4, 2018 D File 021-313807 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Dec 6, 2017 D File 021-300179 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jun 29, 2016 D File 021-266012 | $0 | $0 | $0 Proceeds will be used for general corporate purposes including, but not limited to, executive salaries. | None listed on this filing |
| EDGAR ↗ | Jun 17, 2016 D/A File 021-262245 | $1,081,837 | $11,737 | $0 | Leerink Partners LLC BrokerCheck CRD 39011 ↗ CIM Securities, LLC BrokerCheck CRD 120852 ↗ M.M. Dillon & Co. Group BrokerCheck CRD 19878 ↗ |
| EDGAR ↗ | Jun 17, 2016 D File 021-265295 | $0 | $0 | $0 (est.) | None listed on this filing |
| EDGAR ↗ | Jun 17, 2016 D File 021-265322 | $0 | $0 | $0 (est.) | None listed on this filing |
| EDGAR ↗ | May 4, 2015 D File 021-239073 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Mar 19, 2015 D File 021-236224 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Mar 18, 2015 D File 021-236120 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Sep 30, 2014 D File 021-225555 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Apr 11, 2014 D File 021-215407 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jun 18, 2013 D/A File 021-188154 | $200,000 | $0 | $1,349,674 The amount will be used to repurchase shares of capital stock from certain executive officers. | Madison Park Group BrokerCheck CRD 125475 ↗ |
| EDGAR ↗ | Aug 31, 2012 D File 021-183494 | $0 | $0 | $0 (est.) Proceeds will be used for general corporate purposes including, but not limited to, executive salaries. | None listed on this filing |
| EDGAR ↗ | Apr 20, 2012 D File 021-177000 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jan 5, 2012 D/A File 021-150993 | $0 (est.) | $0 | $0 (est.) An affiliate of the General Partner will receive a fee for management services. Amount to be paid, number of years to be paid and extent to be paid out of adjusted gross proceeds unknown at this time. | Mallory Capital Group, LLC BrokerCheck CRD 108486 ↗ Atlantic-Pacific Capital, Inc. BrokerCheck CRD 38356 ↗ |
| EDGAR ↗ | Nov 15, 2011 D File 021-168716 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Aug 8, 2011 D/A File 021-155941 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Mar 2, 2011 D/A File 021-153306 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Mar 2, 2011 D File 021-156088 | $0 | $0 | $2,279,507 (est.) This estimate excludes amounts paid and that may be paid to the law firm which two executive officers were/are affiliated. | None listed on this filing |
| EDGAR ↗ | Sep 16, 2010 D File 021-147844 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jul 12, 2010 D File 021-144770 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jun 18, 2010 D File 021-143695 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | May 14, 2010 D File 021-142039 | $0 | $0 | $723,000 (est.) This estimate excludes amounts paid and that may be paid to the law firm which two executive officers were/are affiliated and also excludes amounts previously received from the issuance of convertible promissory notes that were converted in the financing. | None listed on this filing |
| EDGAR ↗ | Apr 14, 2010 D File 021-140582 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jan 13, 2010 D File 021-93448 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Dec 21, 2009 D File 021-137023 | $0 | $0 | $93,848,838 Payments represent dividends being paid as permitted by North Carolina law. | None listed on this filing |
| EDGAR ↗ | Aug 13, 2009 D File 021-46875 | $0 | $0 | $0 | None listed on this filing |
As reported by the issuer on Form D (Items 12–15), latest filing per offering (one offering = one SEC file number; an amendment updates its offering rather than adding one). "To insiders" = gross proceeds used for payments to executive officers, directors or promoters. "—" = not reported on that filing. Amounts marked (est.) were reported as estimates. "Paid to sell it" = sales compensation recipients named on that filing (Item 12), each linked to FINRA BrokerCheck when a CRD number is reported.
Counted across every filing this person is listed on (latest filing per offering, per issuer).
| Source | Issuer | Role | Filed | Form | Offering | Sold | Investors | Min. investment |
|---|---|---|---|---|---|---|---|---|
| EDGAR ↗ | Ollin Biosciences, Inc. | Director | Jun 24, 2026 | D | $330,000,000 similar: $2,000,000–$19,999,994 | $156,249,990 | 32 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Monograph Capital Partners II, L.P. group: Monograph | Executive Officer Indirect control person of the Issuer's General Partner | Mar 7, 2025 | D/A | Indefinite similar: $500,000–$16,420,250 | $153,695,000 | 48 similar: 2–28 | No minimum reported similar: $5,000–$100,000 |
| EDGAR ↗ | ASCEND ADVANCED THERAPIES GROUP, INC. | Director | Nov 21, 2024 | D | $130,574,171 similar: $500,000–$7,000,000 | $130,574,171 | 9 similar: 2–14 | No minimum reported similar: $5,000–$50,000 |
| EDGAR ↗ | Monograph Capital Partners II, L.P. group: Monograph | Executive Officer Indirect control person of the Issuer's General Partner | Mar 14, 2024 | D | Indefinite similar: $500,000–$16,420,250 | $0 | 0 similar: 2–28 | No minimum reported similar: $5,000–$100,000 |
| EDGAR ↗ | Kyverna Therapeutics, Inc. | Director | Nov 7, 2023 | D | $151,999,981 similar: $2,000,000–$19,999,994 | $151,999,981 | 24 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Ascend Gene & Cell Therapies Ltd. | Director | Mar 1, 2023 | D | $66,624,999 similar: $500,000–$7,000,000 | $66,624,999 | 10 similar: 2–14 | No minimum reported similar: $5,000–$50,000 |
| EDGAR ↗ | Monograph Capital Partners I, L.P. group: Monograph | Executive Officer Indirect control person of the Issuer's General Partner | Jun 14, 2021 | D | Indefinite similar: $500,000–$16,420,250 | $0 | 0 similar: 2–28 | No minimum reported similar: $5,000–$100,000 |
| EDGAR ↗ | VIDA VENTURES II-A, LLC group: Tishman Speyer | Executive Officer | Jul 16, 2019 | D | $600,000,000 similar: $155,000–$5,250,000 | $15,995,000 | 10 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | Vida Ventures II, LLC group: Tishman Speyer | Executive Officer | Jul 15, 2019 | D | $600,000,000 similar: $155,000–$5,250,000 | $536,740,000 | 109 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | Asklepios BioPharmaceutical, Inc. | Director | May 29, 2019 | D | $199,717,114 similar: $2,000,000–$19,999,994 | $199,717,114 | 33 similar: 2–16 | $101,272 similar: $10,000–$50,000 |
| EDGAR ↗ | VV ATREUS SPECIAL FUND LLC group: Tishman Speyer | Executive Officer | Apr 22, 2019 | D | $60,000,000 similar: $155,000–$5,250,000 | $60,000,000 | 49 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | VVAG Special Fund LLC group: Tishman Speyer | Executive Officer | Jun 4, 2018 | D | $40,000,000 similar: $155,000–$5,250,000 | $40,000,000 | 48 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | Vida Ventures, LLC group: Tishman Speyer | Executive Officer | Dec 6, 2017 | D | $254,800,000 similar: $155,000–$5,250,000 | $254,800,000 | 58 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | Progyny, Inc. | Director | Jun 29, 2016 | D | $20,000,000 similar: $829,831–$9,999,998 | $14,773,147 | 9 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | Cell Design Labs, Inc. | Executive Officer, Director, Promoter | Jun 17, 2016 | D | $4,000,000 similar: $2,000,000–$19,999,994 | $4,000,000 | 1 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | CareDx, Inc. | Director | Jun 17, 2016 | D/A | $36,802,008 similar: $2,000,000–$19,999,994 | $22,169,135 | 42 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Cell Design Labs, Inc. | Executive Officer, Director, Promoter | Jun 17, 2016 | D | $22,890,007 similar: $2,000,000–$19,999,994 | $22,890,007 | 15 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | CareDx, Inc. | Director | Apr 28, 2016 | D | $36,802,008 similar: $2,000,000–$19,999,994 | $14,169,129 | 39 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | RAPID MICRO BIOSYSTEMS, INC. | Director | May 4, 2015 | D | Indefinite similar: $829,831–$9,999,998 | $18,679,991 | 18 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | Progyny, Inc. | Director | Mar 19, 2015 | D | $40,999,999 similar: $829,831–$9,999,998 | $34,324,111 | 29 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | RAPID MICRO BIOSYSTEMS, INC. | Director | Mar 18, 2015 | D | Indefinite similar: $829,831–$9,999,998 | $6,000,000 | 6 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | VERACYTE, INC. | Director | Sep 30, 2014 | D | $12,797,283 similar: $829,831–$9,999,998 | $12,797,283 | 6 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | RAPID MICRO BIOSYSTEMS, INC. | Director | Apr 11, 2014 | D | Indefinite similar: $829,831–$9,999,998 | $6,001,413 | 9 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | Reval Holdings Inc | Director | Jun 18, 2013 | D/A | $19,930,724 | $19,930,724 | 14 | No minimum reported |
| EDGAR ↗ | Reval Holdings Inc | Director | Dec 11, 2012 | D | $10,000,000 | $6,000,000 | 3 | No minimum reported |
| EDGAR ↗ | CARDIODX INC | Director | Aug 31, 2012 | D | $58,018,795 | $30,509,397 | 28 | No minimum reported |
| EDGAR ↗ | FIVE PRIME THERAPEUTICS INC | Director | Apr 20, 2012 | D | $10,000,000 | $10,000,000 | 1 | No minimum reported |
| EDGAR ↗ | NovaQuest Pharma Opportunities Fund III, L.P. group: Novaquest | Director Director of the GP LTD. | Jan 5, 2012 | D/A | $500,000,000 | $182,099,500 | 7 | No minimum reported |
| EDGAR ↗ | CareDx, Inc. | Director | Nov 15, 2011 | D | $2,928,943 | $2,155,781 | 31 | $1 |
| EDGAR ↗ | NovaQuest Pharma Opportunities Fund III, L.P. group: Novaquest | Director Director of the GP LTD. | Oct 7, 2011 | D/A | $500,000,000 | $177,099,500 | 6 | No minimum reported |
| EDGAR ↗ | NODALITY, INC. | Director | Aug 8, 2011 | D/A | $10,000,000 | $9,999,999 | 8 | $100 |
| EDGAR ↗ | Reval Holdings Inc | Director | Mar 2, 2011 | D/A | $23,022,153 | $23,022,153 | 13 | No minimum reported |
| EDGAR ↗ | CARDIODX INC | Director | Mar 2, 2011 | D | $78,325,737 | $57,491,448 | 17 | No minimum reported |
| EDGAR ↗ | NODALITY, INC. | Director | Feb 28, 2011 | D | $10,000,000 | $4,999,999 | 8 | $100 |
| EDGAR ↗ | Reval Holdings Inc | Director | Jan 10, 2011 | D | $22,500,001 | $20,000,001 | 4 | No minimum reported |
| EDGAR ↗ | NovaQuest Pharma Opportunities Fund III, L.P. group: Novaquest | Director Director of the GP LTD. | Nov 24, 2010 | D | $500,000,000 | $177,099,500 | 6 | No minimum reported |
| EDGAR ↗ | FIVE PRIME THERAPEUTICS INC | Director | Sep 16, 2010 | D | $7,499,999 | $7,499,999 | 1 | No minimum reported |
| EDGAR ↗ | CareDx, Inc. | Director | Jul 12, 2010 | D | $10,000,000 | $6,041,511 | 48 | $1 |
| EDGAR ↗ | VERACYTE, INC. | Director | Jun 18, 2010 | D | $28,435,000 | $9,311,668 | 9 | No minimum reported |
| EDGAR ↗ | CARDIODX INC | Director | May 14, 2010 | D | $44,536,736 | $34,564,513 | 16 | No minimum reported |
| EDGAR ↗ | PROTEOGENIX INC | Director | Apr 14, 2010 | D | $4,400,000 | $4,000,000 | 5 | No minimum reported |
| EDGAR ↗ | NODALITY, INC. | Director | Jan 13, 2010 | D | $13,500,000 | $9,999,997 | 4 | No minimum reported |
| EDGAR ↗ | Quintiles Transnational Holdings Inc. | Director | Dec 21, 2009 | D | $525,000,000 | $525,000,000 | 2 | $150,000,000 |
| EDGAR ↗ | Quintiles Transnational Holdings Inc. | Director | Dec 18, 2009 | D | $3,225,011,208 | $3,225,011,208 | 49 | No minimum reported |
| EDGAR ↗ | NODALITY, INC. | Director | Oct 28, 2009 | D | $10,000,000 | $3,499,999 | 1 | No minimum reported |
| EDGAR ↗ | NODALITY, INC. | Director | Oct 26, 2009 | D | $10,000,000 | $3,499,999 | 1 | No minimum reported |
| EDGAR ↗ | PROTEOGENIX INC | Director | Aug 13, 2009 | D | $4,002,500 | $4,002,500 | 5 | No minimum reported |
Every row is a Form D or D/A on which the issuer listed this name as a related person. Related-person names are matched on first + last name and the address state on the filing; records that share a name but could not be tied together by a second identifier are listed separately below.
"Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years (5 industry/exemption sets on this page); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Separate person records under the same name, not combined with this page. Each line says whether it is listed on an issuer this record is also listed on (a second identifier); where it is not, it could be the same person or a different one.
People and management entities the issuers listed as related persons on the same Form D filings as Fred Cohen. Source: the EDGAR rows in the table above. Showing the 40 with the most shared filings.
None found in sources searched.
Sources searched: SEC Regulation A Data Sets (Forms 1-A, 1-K, 1-Z; 2015 Q2 → 2026 Q3); SEC Crowdfunding Offerings Data Sets (Form C family; 2016 Q2 → 2026 Q3); EDGAR form index for 2026 Q3 → 2026 Q4 · Last checked Oct 23, 2026, 8:41 PM ET.
Export this report as PDF (members · included free during the launch period)
No corrections have been requested for this page.
Free. Logged with status: received → under review → fixed / confirmed with source.
If this is you or your firm, add a sourced explanation next to any fact. Reviewed before publishing.
Members get an email when Fred Cohen appears on a new Form D, or when a court case or SEC action is matched to them. See plans →